(HCA), we previously identified a new diagnostic biomarker for a distinctive subtype of HCA with high risk of bleeding, already validated on a multicenter cohort (Henriet E, et al, Hepatology, 2017 and Sala M, et al, Hepatology Communications).
Through an exploratory proteomic approach based on typical hepatocellular adenomas (HCA), we previously identified a new diagnostic biomarker for a distinctive subtype of HCA with high risk of bleeding, already validated on a multicenter cohort (Henriet E, et al, Hepatology, 2017 and Sala M, et al, Hepatology Communications).